引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 66次   下载 19 本文二维码信息
码上扫一扫!
瑞舒伐他汀联合美托洛尔缓释片对慢性心力衰竭患者的疗效及其血清因子的影响
王太昊,董磊,崔晓燕,田徐露
0
(海南省人民医院保健中心;同济大学附属同济医院心内科)
摘要:
【摘要】目的 探讨瑞舒伐他汀联合美托洛尔缓释片对慢性心力衰竭患者的疗效及对血清内皮素1(ET1)、一氧化氮(NO)、血管内皮生长因子(VEGF)、C反应蛋白(CRP)的影响。 方法 选择2015年1月~2017年1月我院接诊的92例慢性心力衰竭患者,通过随机数表法分为观察组和对照组,每组各46例,在常规治疗基础上,对照组使用美托洛尔缓释片治疗,观察组在对照组基础上联合瑞舒伐他汀治疗,均连续治疗3个月。比较两组临床疗效及治疗前后血清ET1、NO、VEGF、CRP、心功能以及6min步行距离的变化。结果 两组血清ET1、CRP均较治疗前显著降低,血清NO、VEGF较治疗前显著增加(P<0.05),观察组血清ET1、CRP明显比对照组低,血清NO、VEGF明显高于对照组(P<0.05);两组左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)较治疗前明显降低,左室射血分数(LVEF)明显升高(P<0.05),观察组LVEDD、LVESD明显低于对照组(P<0.05),LVEF明显比对照组高(P<0.05);两组6min步行距离较治疗前明显增加(P<0.05),治疗后观察组6min步行距离明显长于对照组(P<0.05);观察组临床疗效总有效率明显高于对照组(P<0.05)。结论 在慢性心力衰竭患者中使用瑞舒伐他汀联合美托洛尔缓释片治疗效果显著,可明显改善患者心功能,提高运动功能,其内在机制和有效调节血清ET1、NO、VEGF、CRP的表达相关。
关键词:  慢性心力衰竭  瑞舒伐他汀  美托洛尔缓释片  血清因子  疗效
DOI:
基金项目:上海市科委项目(09JC1413400)
Curative efficacy of rosuvastatin combined with metoprolol sustained release tablets in treatment of chronic heart failure and its effects on serum ET 1, NO, VEGF and CRP levels
WANG Taihao,DONG Lei,CUI Xiaoyan,TIAN Xulu
(Health Center, Hainan Provincial People's Hospital;Department of Cardiology, Tongji Hospital Affiliated to Tongji University)
Abstract:
【Abstract】 Objective To study curative efficacy of rosuvastatin combined with metoprolol sustained release tablets in treatment of chronic heart failure and its effects on serum ET1, NO, VEGF and CRP levels. Methods 92 patients of chronic renal failure received therapy from January 2015 to January 2017 in our hospital were selected. According to random number table, those patients were divided into the observation group (n=46) and the control group (n=46). On the basis of conventional treatment, the control group was treated with metoprolol sustained release tablets, while the observation group was combined with rosuvastatin, they were treated continuously for 3 months. The changes of serum ET1, NO, VEGF, CRP, heart function and 6min walking distance were compared between the two groups before and after treatment, and clinical efficacy was compared. Results After treatment, the serum ET1 and CRP levels in the two groups were significantly lower than those before treatment, and serum NO and VEGF levels significantly increased(P<005), the serum ET1 and CRP levels in the observation group were significantly lower than those in the control group, and the serum NO and VEGF levels were significantly higher than those in the control group(P<005); after treatment, the left ventricular end diastolic diameter (LVEDD) and the left ventricular end systolic diameter (LVESD) in the two groups were significantly lower than those before treatment, the left ventricular ejection fraction (LVEF) significantly increased(P<005), the LVEDD and LVESD in the observation group were significantly lower than those in the control group, and LVEF was significantly higher than those in the control group(P<005); after treatment, the 6min walking distance in two groups was significantly increased than those before treatment(P<005), the 6min walking distance in observation group was longer than those in the control group(P<005); the total effective rate in the observation group was significantly higher than those in the control group((P<005). Conclusion Rosuvastatin combined with metoprolol sustained release tablets is well for chronic renal failure, which can effectively improve the heart function and motor function, it’s intrinsic mechanism is related to the effective regulation of serum ET1, NO, VEGF and CRP expression.
Key words:  Chronic heart failure  Rosuvastatin  Metoprolol sustained release tablets  Serum factor  Curative efficacy

用微信扫一扫

用微信扫一扫